tiprankstipranks

Armata Pharmaceuticals completes enrollment of Phase 1b/2a diSArm study

Armata Pharmaceuticals (ARMP) announced that it has achieved full enrollment of its Phase 1b/2a diSArm study of intravenous AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia. Armata anticipates topline data from the diSArm study in the first quarter of 2025.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue